Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI8852 for influenza treatment
NCT03903718Phase 2Withdrawn
- Sponsor
- MedImmune
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of MEDI8852 in influenza (6 arms), sponsored by MedImmune. Primary endpoints: Incidence of solicited influenza symptoms, TEAEs, TESAEs, and TEAESIs - part 1 and Quantification of influenza viral shedding by qRT-PCR. Planned start Apr 2020; status: withdrawn.
02
Drugs
MEDI8852
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03903718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903718.